Fulgent Genetics, Inc. (NASDAQ:FLGT) CEO Sells $40,665.02 in Stock

Fulgent Genetics, Inc. (NASDAQ:FLGT) CEO Ming Hsieh sold 2,227 shares of the stock in a transaction that occurred on Monday, November 25th. The shares were sold at an average price of $18.26, for a total value of $40,665.02. Following the completion of the sale, the chief executive officer now directly owns 703,711 shares of the company’s stock, valued at $12,849,762.86. The trade was a 0.32 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

Fulgent Genetics Trading Up 1.0 %

Fulgent Genetics stock opened at $18.07 on Thursday. The stock has a 50 day moving average of $19.96 and a two-hundred day moving average of $21.16. Fulgent Genetics, Inc. has a twelve month low of $16.56 and a twelve month high of $30.68. The stock has a market capitalization of $552.76 million, a price-to-earnings ratio of -3.27 and a beta of 1.51.

Analysts Set New Price Targets

FLGT has been the subject of several research reports. Piper Sandler reduced their price target on shares of Fulgent Genetics from $26.00 to $22.00 and set a “neutral” rating for the company in a research report on Monday, November 11th. StockNews.com lowered shares of Fulgent Genetics from a “hold” rating to a “sell” rating in a research note on Wednesday.

Institutional Investors Weigh In On Fulgent Genetics

Several hedge funds have recently modified their holdings of FLGT. Caxton Associates LP acquired a new position in Fulgent Genetics in the 2nd quarter valued at $492,000. Divisadero Street Capital Management LP lifted its stake in shares of Fulgent Genetics by 46.4% in the 2nd quarter. Divisadero Street Capital Management LP now owns 505,212 shares of the company’s stock worth $9,912,000 after acquiring an additional 160,212 shares during the period. Algert Global LLC boosted its holdings in shares of Fulgent Genetics by 46.1% in the second quarter. Algert Global LLC now owns 81,440 shares of the company’s stock valued at $1,598,000 after acquiring an additional 25,680 shares in the last quarter. Acadian Asset Management LLC increased its stake in shares of Fulgent Genetics by 593.5% during the second quarter. Acadian Asset Management LLC now owns 62,724 shares of the company’s stock worth $1,227,000 after acquiring an additional 53,680 shares during the period. Finally, State Board of Administration of Florida Retirement System acquired a new position in shares of Fulgent Genetics during the first quarter worth about $178,000. 48.06% of the stock is owned by institutional investors and hedge funds.

About Fulgent Genetics

Fulgent Genetics, Inc, together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company’s clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases.